Billion-Dollar Showdown Over Metsera Intensifies Between Novo Nordisk and Pfizer

Post by : Bianca Suleiman

A rare takeover confrontation has broken out as pharmaceutical leaders Novo Nordisk and Pfizer reopened bids for Metsera, a three-year-old biotech focused on obesity therapies. Novo Nordisk increased its offer to value Metsera at $10 billion, up from a prior $9 billion proposal, while Pfizer raised its competing bid to $8.1 billion from $7.3 billion.

Despite employing just over 100 staff and having no approved products on the market, Metsera has become the focal point of an aggressive acquisition push. The weight-loss treatment sector, currently estimated at $72 billion, is projected to expand sharply toward 2030, intensifying interest in promising pipelines.

Investor reaction was immediate: Metsera’s shares jumped 20% to $73.18 after the renewed offers. In contrast, Pfizer’s stock eased about 1.5%, while Novo Nordisk’s American depositary receipts slipped roughly 1.8%.

Pfizer has underscored that its proposal already secured U.S. antitrust clearance, describing Metsera’s mix of injectables and oral candidates as a strategic entry point into the lucrative obesity market and citing its own cardiovascular expertise as complementary to the target’s assets.

Novo Nordisk — a pioneer in modern weight-loss drugs that has recently faced setbacks in its research pipeline — is pursuing Metsera to bolster its position. The rivalry has spilled into the courts: Pfizer filed litigation in Delaware Chancery and federal courts seeking to block Metsera from switching merger partners, citing potential competitive and regulatory issues.

The escalating bids and concurrent legal actions reflect the ferocious competition for leadership in obesity therapeutics. Industry analysts say such high-profile deal disputes are uncommon and underscore how pivotal the obesity-drug market has become to pharmaceutical growth strategies.